A recent investigation revealed that among the MPN cohort, the proportion of CCR2+ cells is significantly associated with the severity of myelofibrosis in patients, and CCR2 expression on CD34+ cells correlates with higher-risk classifications in MF and the presence of circulating blast cells (118). The gene discussed is CCR2; the disease is myeloproliferative neoplasm.